Francisco Hernández-Bernal, Arístides Aguilar-Betancourt, Virginia Aljovin, Gloria Arias, Carmen Valenzuela, Karen Pérez de Alejo, Karina Hernández, Orcilia Oquendo, Niurka Figueredo, Nelvis Figueroa, Alexis Musacchio, Gloria Véliz, Elizeth García, Alina D Mollineda, Ana Isabel Juvier, Janette Trujillo, Aurora Delahanty, D Ortega, Z Cinza, Verena L Muzio González
A post-marketing, double blind, randomised, controlled clinical trial to assess the immunogenicity and safety profiles of four commercially available recombinant hepatitis B vaccines was performed. The vaccines included in this study were Heberbiovac-HB (®) (Heber Biotec S.A., Havana, Cuba), Euvax-B (®) (LG Chemical Ltd., Seoul, Korea), Hepavax-Gene (®) (Greencross Vaccine Corp., Seoul, Korea), and Engerix-B (®) (GlaxoSmithKline Biologicals, Rixensart, Belgium). Vaccines were administered intramuscularly to healthy adults in three 20mg doses at monthly intervals (0 - 1 - 2 months)...
October 2011: Human Vaccines